To the Editor Drs Fralick and Kesselheim1 raised concerns about desmopressin nasal spray (Noctiva, Serenity Pharmaceuticals), its approval by the US Food and Drug Administration (FDA) for nocturia, potential safety issues, and clinical effectiveness. Their Viewpoint contains misstatements involving the clinical data, the program, and the basis for FDA approval.
Fein S, Herschkowitz S. Low-Dose Desmopressin Nasal Spray and FDA Approval. JAMA. 2017;318(11):1070–1071. doi:10.1001/jama.2017.11327
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: